A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
- Sponsor:
- Academic GI Cancer Consortium (AGICC)
- Sponsor Study ID:
- CCR-AGICC-Fruq-004
- CTO #:
- 104245
- NCT Number:
- NCT06992258
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Colon; Rectum
- Study Objectives:
- To estimate the progression-free survival (PFS) benefit of fruquintinib in combination with TAS-102 as compared to fruquintinib in patients with locally advanced/metastatic refractory mismatch repair proficient (MMRp) CRC.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Dincman, Toros, at dincmant@musc.edu .
- Study Coordinator, Concepcion, Holly, at concepch@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina